Mucopolysaccharidosis ppt

Mucopolysaccharidosis - SlideShar

Mucopolysaccharidosis • Long unbranched polysaccharides consisting of a repeating disaccharide unit. • Mucopolysaccharidosis are a Hereditary disorder. • This diseases caused by mutations of genes coding for lysosomal enzymes. • This is needed to degrade glycosaminoglycans (GAGs) (acid mucopolysaccharides). • Long-chain complex. Summary Ross CJ, Bastedo L, Maier SA, Sands MS, Chang PL. Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells. Hum Gene Ther. Oct 10 2000;11(15):21172

Mucopolysaccharidosis Treatment Market Growth, Size, Share, Global Analysis, Development and Forecast till 2026 - The global mucopolysaccharidosis treatment market size is predicted to reach USD 4.37 billion by 2026, exhibiting a CAGR of 10.4% during the forecast period. | PowerPoint PPT presentation | free to vie mucopolysaccharidosis dr jerome elusiyan paed. endocrinology fellowship, nairobi, kenya outline introduction pathogenesis/pathology types clinical features diagnosis - A free PowerPoint PPT presentation (displayed as a Flash slide show) on PowerShow.com - id: 472c9b-Nzc5 Mucopolysaccharidoses • Mucopolysaccharidoses (MPS) are lysosomal storage disorders caused by the deficiency of enzymes required for breakdown of glycosaminoglycans (GAGs). • GAGs accumulate in the lysosomes, resulting in cellular dysfunction and clinical abnormalities. 6. Pathophysiology • Mucopolysaccharidoses are hereditary. Mucopolysaccharidosis Treatment Market Growth, Size, Share, Global Analysis, Development and Forecast till 2026 - The global mucopolysaccharidosis treatment market size is predicted to reach USD 4.37 billion by 2026, exhibiting a CAGR of 10.4% during the forecast period View Mucopolysaccharidosis I Mps I PPTs online, safely and virus-free! Many are downloadable. Learn new and interesting things. Get ideas for your own presentations. Share yours for free

Mucopolysaccharidosis type III is a group PPT Presentation Summary : MPS III or Sanfilippo syndrome. Mucopolysaccharidosis type III is a group of five autosomal recessive lysosomal storage disorders leading to tissue accumulatio Mucopolysaccharidosis (MPS) is a group of rare, hereditary and incurable storage diseases. MPS is named after mucopolysaccharides (sugars bound to proteins), which are not broken down correctly in these diseases, causing the products of incomplete metabolism to accumulate in the body. The stored mucopolysaccharides, nowaday Mucopolysaccharidosis I Pipeline Review, H1 2015 - RnRMarketResearch.com adds Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Pipeline Review, H1 2015 to its store. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete with comparative analysis at various stages RnRMarketResearch.com adds Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Pipeline Review, H1 2015 to its store. This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete with comparative analysis at various stages. - A free PowerPoint PPT presentation (displayed as a Flash slide show) on PowerShow.

Mucopolysachridosis - SlideShar

PPT - Mucopolysaccharidosis PowerPoint Presentation, free

Mucopolysaccharidosis type IV (MPS IV), also known as Morquio syndrome, is a rare metabolic condition in which the body is unable to break down long chains of sugar molecules called glycosaminoglycans. As a result, toxic levels of these sugars accumulate in cell structures called lysosomes, leading to the various signs and symptoms associated with the condition Mucopolysaccharidosis type III (MPS III), also known as Sanfilippo syndrome, is a progressive disorder that primarily affects the brain and spinal cord (central nervous system). It is characterized by deterioration of neurological function (neurodegeneration), resulting in many of the features of the condition. Explore symptoms, inheritance, genetics of this condition Mucopolysaccharidosis in a 4-year-old boy with Hurler disease. (a) T1-weighted MR image shows multiple well-defined areas of low signal intensity in the central and subcortical white matter. (b) T2-weighted MR image demonstrates multiple well-defined areas of high signal intensity in the deep and subcortical white matter

Mucopolysaccharidosis - . james montgomery december 20, 2010. accession #: 50070. fluffy 5 month old, male collie mix Mucopolysaccharidosis , ppt - Mucopolysaccharidosis, ppt, Spinal cord compression in mucopolysaccharidosis - . agnes chen, md k30 case study 23 march 2010. 9 year old girl wit Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) - Pipeline Review, H2 2015 Summary Global Markets Direct s, Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome) - Pipeline Review, H2 2015 , provides an overview of the Mucoread more SlideOnline. Browser Featured Presentations. Wheel Diagram Template for PowerPoint. Mucopolysaccharidosis type I: clinical and biochemical study. East Mediterr Health J. 2000 Mar-May. 6 (2-3):359-66. . Jones KL, Jones MC, del Campo Avenelles M. Storage disorders. Smith's Recognizable Patterns of Human Malformation. 7th ed. Philadelphia: Elsevier Saunders; 2013. 594-611. Muenzer J. Mucopolysaccharidoses.. Mucopolysaccharidosis type I (MPS I) is a condition that affects many parts of the body. It is a progressively debilitating disorder; however, the rate of progression varies among affected individuals. MPS I is caused by mutations in the IDUA gene

PPT - Mucopolysaccharidosis PowerPoint presentation free

PPT - MUCOPOLYSACCHARIDOSIS PowerPoint presentation free

  1. Guidelines for diagnosis and treatment of Hunter Syndrome for clinicians in Latin America Roberto Giugliani1,2,3, Martha Luz Solano Villarreal4, C. Araceli Arellano Valdez5, Antonieta Mahfoud Hawilou6, Norberto Guelbert7, Luz Norela Correa Garzón8, Ana Maria Martins9, Angelina Acosta10, Juan Francisco Cabello11, Aída Lemes12, Mara Lucia Schmitz Ferreira Santos13 and Hernán Amartino1
  2. Mucopolysaccharidosis type I (MPS I) is a condition that affects many parts of the body. This disorder was once divided into three separate syndromes: Hurler syndrome (MPS I-H), Hurler-Scheie syndrome (MPS I-H/S), and Scheie syndrome (MPS I-S), listed from most to least severe
  3. oglycans (GAGs). In affected patients, one or more of three specific polymers—dermatan sulfate (DS), heparan sulfate (HS), and keratan sulfate (KS)—accumulate within the cells, interfering with normal function, and.
  4. Mucopolysaccharidosis type I affects males and females in equal numbers, with an incidence of about 1 in 100,000 live births for the severe type, and an incidence of about 1in 500,000 live births for the attenuated type. Incidence is the number of people who develop a disorder over a given period of time (e.g. one year). The incidence for MPS.
  5. oglycans. This test includes quantitative measurement of total glycosa

Mucopolysaccharidoses in children - SlideShar

  1. Mucopolysaccharidosis type VI (MPS VI), also known as Maroteaux-Lamy syndrome, is a progressive condition that causes many tissues and organs to enlarge, become inflamed or scarred, and eventually waste away (atrophy). Explore symptoms, inheritance, genetics of this condition
  2. Mucopolysaccharidosis I (MPS I) is a rare genetic disorder that affects both physical and mental development and can cause organ damage
  3. oglycans (formerly called mucopolysaccharides)
  4. CrossRef. adh is produced in a part of the brain called the hypothalamus View and Download PowerPoint Presentations on Mucopolysaccharidosis PPT. These tests in some Como Hacer Un Curriculum Vitae Chile 2010 Con Plantilla form have been available in the United States since the 1930s. Apr 01, 2000 · The incidence of diabetes insipidus in the.
  5. oglycans (also known as GAGs or mucopolysaccharides ). The mucous cells of each kind of fish skin were divided into four types by AB-PAS staining: type I.

Mucopolysaccharidosis I PowerPoint PPT Presentation

Neonatal anemia and the need for red blood cell (RBC) transfusions are very common in neonatal intensive care units. Neonatal anemia can be due to blood loss, decreased RBC production, or increased destruction of erythrocytes. Physiologic anemia of the newborn and anemia of prematurity are the two m Animals, animal samples, and pedigrees. The animals in this study were from a long-standing canine colony characterized at the University of Tennessee and founded by Plott hounds carrying the lethal and progressive lysosomal storage disease MPS I. 19 Beagles were used for outcrossing during the maintenance of this colony. Eleven animals were transferred to Iowa State University (Ames, Iowa. With the exception of MPS II (Hunter syndrome; X-linked), MPS are inherited in an autosomal recessive manner. In affected individuals, 1 or more specific GAGs—dermatan sulfate (DS), heparan sulfate (HS), keratan sulfate (KS), and chondroitin-6-sulfate—accumulate within the lysosomes, interfering with recycling of cellular material ().GAGs build up in the lysosome over time, affecting.

Mucopolysaccharidosis I Mps I PowerPoint PPT Presentation

  1. SUPPORT/MEMBERSHIP: https://www.youtube.com/channel/UCZaDAUF7UEcRXIFvGZu3O9Q/join INSTAGRAM: https://www.instagram.com/dirty.medicin
  2. Brain MRI findings in patients with mucopolysaccharidosis types I and II and mild clinical presentation. Neuroradiology 2004;46(8):666-672. Crossref, Medline, Google Scholar; 5 Müller-Forell W, Frenking GS, Amraoui Y, Beck M. Mucopolysaccharidoses (MPS): clinical and neuroradiological aspects of the different types
  3. View large Download PPT. A 6-year-old girl from Pakistan was investigated for neurologic symptoms also affecting 3 other family members. She was the sixth child of parents who were first cousins, born at term with normal birth weight. which are typical of some types of mucopolysaccharidosis (MPS) storage disorder
  4. The COVID-19 pandemic is a huge challenge to education systems. This Viewpoint offers guidance to teachers, institutional heads, and officials on addressing the crisis. What preparations should institutions make in the short time available and how do they address students' needs by level and field o
  5. oglycans (GAGs) within the lysosomes
  6. istration (FDA) on treatments approved for rare diseases, known as orphan products/drugs. The Orphan Drug Act was passed in 1983 to give drug companies incentives to develop treatments for rare diseases. The FDA Office of Orphan Products Development deter
  7. oglycans, composed of a

Mucopolysaccharidosis PPT Xpowerpoin

  1. Mucopolysaccharidosis Lipidosis Gauchers, Niemann Pick, Tay Sachs Tyrosinaemia 5. SPACE OCCUPYING LESIONS Abscess Primary and secondary neoplasms 6. FAT INFILTRATION Malnutrition Hyperalimentation Uncontrolled Diabetes Mellitus Mauriac Syndrome Hepatotoxic drugs TB treatment Reye's Syndrome 7. METABOLIC DISORDER
  2. View large Download PPT. She had a history of Sanfilippo disease (mucopolysaccharidosis type 3B; diagnosed at a different institution) that manifested clinically with severe intellectual disability, chronic respiratory disease with suppurative bronchitis, seizure disorder, obstructive sleep apnea, scoliosis, and required gastrostomy feedin
  3. ide N-acetyltransferase (N-acetyltransferase), which leads to impaired degradation of heparan sulfate. We report the narrowing of the candidate region to a 2.6-cM interval between D8S1051 and D8S1831.
  4. oglycans due to iduronate 2-sulfatase deficiency. This study investigated the pathophysiology of the bone complications associated with mucopolysaccharidosis II and the effect of lentivirus-mediated gene therapy of hematopoietic stem cells on bone lesions of mucopolysaccharidosis type II mouse models in.

  1. Hurler syndrome is the most severe form of MPS-I with death, due to respiratory infection or heart failure, by 10 years of age. The patients appear normal at birth but develop progressive physical and mental abnormalities between 6 and 24 months. The disease is characterized by dwarfism, coarse facial features (Figure 2), lumbar lordosis, stiff joints, chest deformities, deafness, hepatomegaly.
  2. If you have problems viewing PDF files, download the latest version of Adobe Reader. For language access assistance, contact the NCATS Public Information Officer. Genetic and Rare Diseases Information Center (GARD) - PO Box 8126, Gaithersburg, MD 20898-8126 - Toll-free: 1-888-205-231
  3. e 4-sulfatase (4S) leading to the lysosomal accumulation and urinary excretion of dermatan sulfate. MPS VI has also been described in the Siamese cat. As an initial step toward enzyme replacement therapy with recombinant feline 4S (rf4S) in MPS VI cats, the feline 4S cDNA was.
  4. oglycan (GAG) metabolism
  5. Patients with neuronopathic mucopolysaccharidosis II (MPS II) develop severe cognitive impairment and progressive neurological decline. The results of this study by Seo et al. suggest that intracerebroventricular idursulfase beta treatment for 100 weeks is well tolerated and effective at preventing and stabilizing developmental decline in patients with neuronopathic MPS II
  6. istrations of 2.0 mg/kg of pabinafusp alfa.

Mucopolysaccharidosis I Hurler Syndrome PowerPoint PPT

PPT - Mucopolysaccharides PowerPoint Presentation - ID:1158702

PPT - Mucopolysaccharidosis I Pipeline Review, H1 2015

Mucopolysaccharidosis , ppt - Mucopolysaccharidosis, ppt, Spinal cord compression in mucopolysaccharidosis - . agnes chen, md k30 case study 23 march 2010. 9 year old girl with. Spinal cord compression in mucopolysaccharidosis - 9 year old girl with mps i. diagnosed at age 2intravenous enzyme MUCOPOLYSACCHARIDOSIS - authorSTREAM Presentation. CLINICAL FEATURES: CLINICAL FEATURES Presenting features can include delayed development, hyperactivity with aggressive behavior, coarse hair, hirsutism, sleep disorders, and mild hepatosplenomegaly

MPS and ML. Mucopolysaccharidoses (MPS) and mucolipidosis (ML) are genetic lysosomal storage diseases (LSD) caused by the body's inability to produce specific enzymes. The missing or insufficient enzyme prevents cells from recycling waste, resulting in the storage of materials in cells throughout the body. As the disease progresses, there is. 6.2 Mucopolysaccharidosis 6.3 Lipid: Gauchers, Niemann Pick, Tay Sachs 6.4 Tyrosinaemia. ∗ 7. FAT ACCUMULATION ∗ 7.1 Malnutrition ∗ 7.2 Hyperalimentation Microsoft PowerPoint - APPROACH TO JAUNDICE APPROACH TO HEPATOSPLENOMEGALY.ppt [Compatibility Mode] Author: use Briefly, urinary GAG was ppt with CPC as described above. The precipitate was dissolved in 2 M lithium chloride, re-ppt in 800 μl absolute ethanol, and centrifuged at 1500 g for 10 min. The pellet was redissolved in 20 μl distilled water with 0.5 g/l phenol red added as a marker. The ppt GAG was stored at 40°C until electrophoresed

PPT - Inborn Errors of Metabolism PowerPoint Presentation

Mucopolysaccharidosis I is a lysosomal storage disease caused by a deficiency of the enzyme alpha-L-iduronidase. We evaluated the effect of enzyme-replacement therapy with recombinant human alpha. • Mucopolysaccharidosis type VII and IV • Gaucher's • Niemann-Pick A & C • I-Cell disease Odour : maple syrup (burnt sugar) sweaty feet odour • MSUD • Isovaleric acidaemia or • Glutaric acidaemia type II Cataracts • Galactosaemia • Zellweger's syndrome Hunter syndrome is a very rare, inherited genetic disorder caused by a missing or malfunctioning enzyme. In Hunter syndrome, the body doesn't have enough of the enzyme iduronate 2-sulfatase. This enzyme's job is to break down certain complex molecules, and without enough of this enzyme, the molecules build up in harmful amounts. The buildup of. Mucopolysaccharidosis (I-IV, VI and VII). The eponymous names are used less frequently now, particularly in the literature, but you might come across them in clinical practice (MPS I, Hurler's Syndrome; MPS II, Hunter's Syndrome; MPS VI, Maroteaux- Lamy) Gaucher diseas

PPT - Morquio A Disease Overview PowerPoint Presentation

PPT - Mucopolysaccharidosis III (MPS III) Market Forecast

In this study, we focused on the occurrence of aortopathy in the mouse models of three LSDs: Pompe disease (PD), Fabry disease (FD), and Mucopolysaccharidosis (MPS) IIIB. PD is a rare autosomal recessive and progressive genetic disorder caused by mutations in the gene encoding for the acid α-glucosidase (GAA), the lysosomal enzyme that. Pabinafusp alfa (JR-141) is a novel enzyme drug that crosses the blood-brain barrier by transcytosis via transferrin receptors. In order to establish its efficacy and safety, a multicenter, single-arm, open-label phase 2/3 clinical trial was conducted in 28 Japanese patients with mucopolysaccharidosis II (MPS-II, Hunter syndrome) by intravenous administrations of 2.0 mg/kg of pabinafusp alfa. Mucopolysaccharidosis type I (MPS I, OMIM 252800) is a rare lysosomal storage disorder caused by the deficiency or complete absence of enzyme α-L-iduronidase activity. Inadequate activity of this enzyme leads to the accumulation of glycosaminoglycans throughout the body, resulting in progressive multisystem deterioration Liver cirrhosis management ppt. Management of decompensated cirrhosis. If patients have a score of 15 or greater they should be referred to a transplant center. Development of variceal hemorrhage and ascites are the direct consequence of portal hypertension while jaundice occurs as a result of a compromised liver function. Class i level b 8

Characteristic ocular features in patients with MPS include corneal clouding, glaucoma, retinopathy, optic disc swelling and optic atrophy. 2-5 Ocular problems in patients with MPS are among the first symptoms to arise and can ultimately result in visual impairment or blindness. 4, 5 This review of the anatomy and physiology of the normal eye and overview of changes in structure and function. Mucopolysaccharidosis type II (MPS II; Hunter Syndrome) is an X-linked inherited lysosomal storage disease caused by deficiency of iduronate-2-sulfatase (IDS) and subsequent accumulation of glycosaminoglycans (GAGs) dermatan and heparan sulphate. Affected individuals exhibit a range in severity of manifestations such as organomegaly, skeletal dysplasias, cardiopulmonary obstruction. Mucopolysaccharidosis type II (Hunter disease, iduronate-2-sulfatase deficiency) was diagnosed in a 4-year-old female by demonstrating low iduronate-2-sulfatase activity both in leukocytes and fibroblasts and by the presence of a novel, complex rearrangement of the iduronate-2-sulfatase gene in heterozygous form. Mucopolysaccharidosis type II is inherited in an X-linked recessive manner and. Quadrupole Analysers. The quadrupole analyser consists of a set of four parallel metal rods (Figure 1).A combination of constant and varying (radio frequency) voltages allows the transmission of a narrow band of m/z values along the axis of the rods. By varying the voltages with time it is possible to scan across a range of m/z values, resulting in a mass spectrum In Australia, mucopolysaccharidosis I is the most common of the mucopolysaccharidosis disorders, with a prevalence of one per 88 000 livebirths. Prevalence of lysosomal storage disorders as a whole is one per 7700 livebirths

Mucopolysaccharidoses Radiology Reference Article

VISUAL ABSTRACT Lower Treatment Threshold for Neonatal Hypoglycemia. Hypoglycemia is the most common metabolic problem in newborns and may lead to persistent brain injury. 1,2 Because neonatal. Clinical and Experimental Ophthalmology 2010; 38: 2-11 doi: 10.1111/j.1442-9071.2010.02363.x Review Anatomy and physiology of the human eye: effects of mucopolysaccharidoses disease on structure and function - a review ceo_2363 2..11 Colin E Willoughby MD, PhD,1 Diego Ponzin MD,2 Stefano Ferrari PhD,2 Aires Lobo MD,3 Klara Landau MD, PhD4 and Yadollah Omidi PhD5 1 Centre for Vision Science. Restrictive Cardiomyopathy. Restrictive cardiomyopathy (RCM) refers to either an idiopathic or a systemic myocardial disorder in the absence of underlying atherosclerotic coronary artery disease, valvular disease, congenital heart disease, or systemic hypertension, which is characterized by abnormal left ventricular filling, and is associated with normal or reduced left ventricle (LV) and.

Disproportionate shortening in patients with mucopolysaccharidosis (1) & an autosomal recessive type of spondylo-epi-metaphyseal dysplasia (2) 27. Facial featuresFacial features yEyebrows e.g. Synophrys (fused eyebrows) yInnercanthal distanc Enzyme replacement therapy (ERT) is available for mucopolysaccharidosis (MPS) I, MPS II, MPS VI, and MPS IVA. The efficacy of ERT has been evaluated in clinical trials and in many post-marketing studies with a long-term follow-up for MPS I, MPS II, and MPS VI. While ERT is effective in reducing urinary glycosaminoglycans (GAGs) and liver and spleen volume, cartilaginous organs such as the. Skeletal dysplasias have also been reported in animals with inherited lysosomal storage diseases such as mucopolysaccharidosis and gangliosidosis. In these individuals, chondrocytes may be vacuolated due to cytoplasmic retention of glycosaminoglycans and lipid. It is likely that chondrocyte function is altered, adversely affecting the process. Congenital posterior fossa abnormalities represent a wide variety of disorders that include both malformations and disruptions. These disorders may involve a single structure within the posterior fossa (eg, the cerebellum alone) or a combination of structures (eg, the pons and cerebellum) Inborn errors of metabolism (IEM), although individually rare, occur in 1 out of every 1,500 births. The first opportunity to detect IEM occurs during preconception counseling, when pregnant women.

Diagnosis and Treatment of Morquio A Syndrome: Expert

Mucopolysaccharidosis - Wikipedi

Achondroplasia is a congenital genetic disorder resulting in rhizomelic dwarfism and is the most common skeletal dysplasia. It has numerous distinctive radiographic features. Epidemiology It occurs due to sporadic mutations in the majority of. Ultrasound. A ureterocele appears as a cystic structure projecting into the bladder, often near the normal location of the vesicoureteric junction (VUJ). This is ectopic in the majority of cases and therefore not at the expected location of the ureteric orifice. The associated ureter is usually noticeably dilated Krabbe disease , also known as globoid cell leukodystrophy , is an autosomal recessive lysosomal storage disorder resulting in damage to cells involved in myelin turnover. It thus affects both the peripheral nervous system and the central nervous system (manifesting as a leukodystrophy ). On this page: Article: Epidemiology. Clinical presentation

Mucopolysaccharidosis (MPS) Gaucher type III White matter Abnormal myelin that breaks down rapidly. These dysmyelinating disorders are called Leukodystrophies-the earliest sign spasticity.-Dementia and seizures Can occur, but later-Extrapyramidal signs Rare, but ataxia due to cerebellar pathway involvement-optic atrophy is the most. Ace medical MCQs is an e book you can access on your smart phone and your tablet. It is a collection of MCQs in all medical subjects prepared by a group of experts in the field. Tuberculosis (TB) 1. AntiTB drug that has bacteriociddal and sterilizing effect on tissue is: A) Rifampicin. B) INH By definition, a dentigerous cyst occurs in association with an unerupted tooth. Most commonly around permanent mandibular third molars (wisdom teeth) Somewhat less common around permanent maxillary third molars, maxillary cuspids and mandibular second premolars but any tooth may be involved Mucopolysaccharidosis type IIIB syndrome is an orphan disease for which no treatment strategy has been investigated in human beings. In studies in mice and dogs, we saw beneficial effects with intracerebral gene therapy administered via a recombinant adenoassociated virus 2/5 vector with concomitant immunosuppression The cause of this could be congenital or acquired which could be due to trauma, infection meningitis/ encephalitis), endocrine (hypothyroidism), nutritional (Vitamin B12 deficiency), tumour, neurometabolic (mucopolysaccharidosis, glycogen storage disorder), epilepsy, Rett syndrome. Notes: If examination is abnormal, 2 questions to ask mother

Hunter Syndrome

PPT - Mucopolysaccharidosis Treatment Market: Global Size

Inborn errors of metabolism (IEMs) are genetic disorders that result from defects in energy production and/or the metabolism of macromolecules. Individually, IEMs are rare diseases; however, collectively they are quite common with an incidence of approximately 1 in 2500 births. These disorders often present with a range of clinical phenotypes. Neuroimmuno. Amyloid-β (Aβ) immunotherapy has recently begun to gain considerable attention as a potentially promising therapeutic approach to reducing the levels of Aβ in the Central Nervous System (CNS) of patients with Alzheimer's Disease (AD). Despite extensive preclinical evidence showing that immunization with Aβ (1-42) peptide can. INTRODUCTION. The introduction of new potassium binders (patiromer and zirconium cyclosilicate) has refocused attention on hyperkalemia. There have also been significant recent advances in our understanding of the mechanisms that maintain potassium homoeostasis and the clinical consequences of hyperkalemia

PPT - Preclinical Safety Assessment of Aptamer